saving lives since 2016
BackgroundAnaphylaxis is a process in which the body produces histamines and other substances in response to an allergen. Anaphylaxis may present as airways tightening, rashes developing, and many other undesirable symptoms and may lead to shock. Anaphylactic shock is fatal if not treated quickly with epinephrine, due to cardiorespiratory collapse. Some of the most recent data suggests that the incidence is approximately 50 to 200 episodes per 100,000 person-years with a lifetime prevalence ranging between 0.05% and 2%. Over 1,500 fatalities are caused by anaphylaxis per year in the United States.
The overall goal of this project is to design a device that can be used in an emergency for someone undergoing anaphylaxis, mainly as a more cost-effective, safe, and efficient alternative to existing devices.
|
Our specific goals include a cheaper device (under $300), a less invasive epinephrine administration method, accomodation for patients of different body types, and an accurate and precise delivered dose of epinephrine.
|
MORE PORTABLEAt the size of your typical smartphone, MediSaver fits easily in your pocket.
|
BETTER DOSAGEAt .3 mg epinephrine for adults and .15 for juniors, our unique mixing technique allows for a wider range of storage temperatures for your convenience.
|
COST EFFECTIVECompared to EpiPen's retail price of over $600, MediSaver will retail for under 1/2 of that price.
|
SAFERMediSaver uses our patent pending needle delivery mechanism that is less intimidating and easier to use.
|
BEHIND THE SCENES OF MEDISAVERA joint collaboration between Washington University in St. Louis's Undergraduate Biomedical Engineering Department and Washington University in St. Louis's School of Medicine -- Allergy, Immunology, and Pulmonary Medicine Department
|